SMP-3124 / Sumitomo Pharma - LARVOL DELTA

Evaluation of SMP-3124, a novel liposome-encapsulated CHK1 inhibitor, in patient-derived preclinical models of treatment-resistant ovarian cancer (AACR 2025) - "We confirmed potent anti-tumor activities of SMP-3124 in multiple preclinical subcutaneous xenograft models without weight loss. To further evaluate the potential of SMP-3124, especially in recurrent ovarian cancer, we established a novel preclinical model from the ascites of a patient with multiple treatment-resistant ovarian cancers. The preclinical study using this model revealed resistance to the standard treatment drugs in ovarian cancer, while showing sensitivity to SMP-3124."

Preclinical • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor

A Phase 1/2 Study of SMP-3124LP in Adults with Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=120 | Recruiting | Sponsor: Sumitomo Pharma America, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Oncology • Solid Tumor

A Phase 1/2 Study of SMP-3124LP in Adults With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=120 | Not yet recruiting | Sponsor: Sumitomo Pharma America, Inc.

Metastases • New P1/2 trial • Oncology • Solid Tumor

Preclinical evaluation of a novel CHK1 inhibitor encapsulated within the liposome, SMP-3124, for the treatment of solid cancer (AACR 2024) - "SMP-3124 synergistically inhibited tumor growth in combination with gemcitabine without additional hematological toxicities induced by gemcitabine. We are planning to an investigational new drug application in 2024."

Preclinical • Oncology • Ovarian Cancer • Solid Tumor